Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Musculoskeletal  |  Oncology

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Bone Neoplasm Clinical Trials

A listing of Bone Neoplasm medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (29) clinical trials

A clinical trial seeking patients for a research study of PF-06801591

Protocol B8011001 is a Phase 1, two part, open-label, multi center, multiple-dose, safety, efficacy, PK, and PD study of PF-06801591 administered intravenously (IV) or subcutaneous (SC) in previously treated adult patients with locally advanced or metastatic melanoma, squamous cell carcinoma head and neck (SCCHN), ovarian carcinoma, sarcoma, non-small cell lung ...


A clinical trial to evaluate treatments using SC SEA-CD40 monotherapy regimen, Pembrolizumab, IV SEA-CD40 monotherapy regimen for patients

The study will be conducted in the following parts: Part A: Intravenous (IV) monotherapy dose-regimen finding for solid tumors -- Dose-escalation, and possible dose-interval modification to lengthen the treatment cycle, to define the IV SEA-CD40 monotherapy maximum tolerated dose (MTD) and/or the optimal biological dose (OBD) regimens in patients with ...


Patients are needed to participate in a clinical research study evaluating Pembrolizumab, Axitinib

The study will be a single-institution, open-label, single-arm phase II study. Since the primary endpoint is survival outcome, progression-free survival (PFS) sample size calculation is based on a single-arm survival design. The investigators will employ early stopping rules for lack of efficacy, based on previously reported historical controls (19% PFS ...


A clinical research study of Durvalumab, Poly ICLC, Tremelimumab

This is an open-label, multicenter Phase 1/2 study of the CTLA-4 antibody, tremelimumab, and the PD-L1 antibody, durvalumab (MEDI4736), in combination with the tumor microenvironment (TME) modulator polyICLC, a TLR3 agonist, in subjects with advanced, measurable, biopsy-accessible cancers.


A clinical trial sponsored by Memorial Sloan Kettering Cancer Center for a research study for the treatment of Sarcoma, liposarcoma

The purpose of this study is to test any good and bad effects of the study drug called Abemaciclib. Abemaciclib could shrink your cancer but it could also cause side effects. Researchers hope to learn if the study drug will delay the growth of the cancer or shrink the cancer ...


Patients are needed to participate in a clinical research study for the treatment of Thrombocytopenia, Pancytopenia, Neutropenia, Hematologic Malignancy, Anemia

This protocol is designed for screening of subjects before a decision can be made as to their eligibility for one of the active Hematology Branch research protocols. Its purpose is to allow detailed investigation into the hematologic or oncologic problems of these subjects, and the status of other organ systems ...

Phase N/A

A clinical trial sponsored by Sidney Kimmel Comprehensive Cancer Center for a research study for the treatment of ESSENTIAL THROMBOCYTHEMIA, Prolymphocytic Leukemia, Chronic Myeloproliferative Disorders, Plasma Cell Neoplasm, Multiple Myeloma, Polycythemia Vera, Monoclonal gammopathy, Chronic myelomonocytic leukemia, Chronic Lymphocytic Leukemia, MYELODYSPLASTIC SYNDROME, Plasma cell leukemia, Chronic myeloid leukemia, Myelosclerosis with myeloid metaplasia, Preleukemia

The main goal is to learn whether a drug called tacrolimus, which is an immune-lowering drug (an immunosuppressant) given after transplant to help prevent certain complications, can be given safely for a shorter period of time than it has been in the past. The experiences with immunosuppression duration with other ...


A clinical trial seeking patients for a research study of MDM2 Inhibitor AMG-232

PRIMARY OBJECTIVES: I. To evaluate the safety and tolerability of MDM2 inhibitor AMG-232 (AMG 232) in combination with standard-dose radiotherapy in soft tissue sarcoma (STS) in two separate patient cohorts (A, extremity or body wall; B, abdomen/pelvis/retroperitoneum). II. To determine the maximum tolerated dose/recommended phase II dose (maximum tolerated dose/recommended ...